A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.

Prior treatment

• Subjects who received live vaccination within 4 weeks before the first dose or were planned to receive live vaccination during the study period and 4 weeks after the dose.
• Major surgery or other treatment or diagnosis that has a significant impact on the participant within 4 weeks before the first dose.

Other illness

• Patients with active, or who have had and have the possibility of recurrence of autoimmune diseases.
• History of severe cardiovascular and cerebrovascular disorder.
• Active infectious disease.
• History of mental illness (interfering with understanding or giving informed consent), drug abuse, alcoholism, or drug addiction.
• The investigator believes that the participant has other conditions that may affect compliance or are not suitable for participating in this study.

Other

• Women during pregnancy or lactation.

• Agree to follow the trial treatment regimen, visit schedule,laboratory test, and comply with other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.
• At the time of signing the informed consent form, the age was ≥ 18 years old, and the gender was not limited.
• The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1.
• The expected survival time is at least 12 weeks.
• According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours）, the subjects enrolled have at least one measurable neoplasm lesion.
• Male of childbearing potential and Females of childbearing age are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug.